Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaMelphalanTransplantation, HomologousTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyBone Marrow TransplantationTreatment OutcomeRemission InductionStem CellsSalvage TherapyBone MarrowDisease-Free SurvivalEtoposideHodgkin DiseaseCyclophosphamideLymphoma, Non-HodgkinMyeloablative AgonistsRecurrenceCytarabineGraft vs Host DiseaseCarmustineBone Marrow PurgingHematopoietic Stem Cell MobilizationSurvival RateBone Marrow CellsThiotepaVincristineHematopoietic Stem CellsHematologic NeoplasmsWhole-Body IrradiationSurvival AnalysisLymphoma, Mantle-CellRetrospective StudiesAmyloidosisBusulfanGraft SurvivalBoronic AcidsDexamethasonePyrazinesPrognosisDoxorubicinAntigens, CD34Antibodies, Monoclonal, Murine-DerivedLymphoma, FollicularFollow-Up StudiesLymphoma, T-Cell, PeripheralAutograftsAntineoplastic Agents, AlkylatingLiver TransplantationThalidomideMesenchymal Stem Cell TransplantationTime FactorsGranulocyte Colony-Stimulating FactorIfosfamidePrednisoneLeukapheresisTransplantation ChimeraLymphomaPodophyllotoxinInduction ChemotherapyAntineoplastic AgentsNeoplasm, ResidualTissue DonorsLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, AcuteMaintenance ChemotherapyCord Blood Stem Cell TransplantationCell TransplantationMyelodysplastic SyndromesKidney TransplantationLymphoma, B-CellEmbryonic Stem CellsEnteropathy-Associated T-Cell LymphomaCell DifferentiationLeukemia, Plasma CellIdarubicinMitoxantroneHematopoiesisInfusions, SpinalBone and BonesNeoplasms, Second PrimaryAdult Stem CellsHistocompatibility TestingImmunosuppressive AgentsBlood Component RemovalProspective StudiesAntibodies, MonoclonalLeukemia, MyeloidLeukemiaMesenchymal Stromal CellsCarboplatinHistocompatibilityFeasibility StudiesFatal OutcomeKeratins, Type II